Lupin-associated U.S. cephalexin records cover more than one dosage-form family. Its DailyMed capsule label includes 250 mg and 500 mg products with LUPIN imprints, while a separately published oral-suspension label describes 125 mg/5 mL and 250 mg/5 mL products after preparation. Those records should be reviewed individually rather than treated as one interchangeable catalog item.
The labels also distinguish the company's roles. Lupin Pharmaceuticals, Inc. is named in U.S. labeling, while the cited capsule and suspension documents identify Lupin Limited in Mandideep, India as the manufacturer. That is a specific documented statement about those records, not a claim about every product ever marketed under the Lupin name. The manufacturer guide explains these distinctions.
This page helps identify Lupin-specific products and ask the pharmacy about a prescription that specifies cephalexin or mentions a particular company. It is not a real-time catalog or a manufacturer endorsement. For the wider generic category visit generic cephalexin; if the issue is whether a specific item is obtainable, see pharmacy supply verification.
Lupin's capsule record carries DailyMed set ID 1d3e6d33-5dc2-498e-8efa-e3c4fca15dff. A separate suspension record uses set ID 25ef498a-7a7e-4543-a544-b9d0e99f9cd9. Looking at the set IDs prevents a pill photograph or a liquid package label from being mistaken for a description of the same finished dosage form.
The capsule label lists ANDA065229 and the suspension label lists ANDA065234. These are identifiers for different regulatory records. A pharmacist can match an actual dispensed package to its form, strength, package identifier and prescription rather than treating a company name as sufficient product identification.
| Lupin product family | Recorded U.S. identifier | Critical verification |
|---|---|---|
| Capsules, 250 mg | NDC 68180-121-01 / -02 | LUPIN / 250 imprint and prescribed capsule strength |
| Capsules, 500 mg | NDC 68180-122-01 / -02 | LUPIN / 500 imprint and prescribed capsule strength |
| Oral suspension, 125 mg/5 mL | NDC 68180-440-01 / -02 | Prepared concentration and total bottle volume |
| Oral suspension, 250 mg/5 mL | NDC 68180-441-01 / -02 | Different mg-per-mL concentration; verify syringe directions |
| Approved application references | ANDA065229 capsules; ANDA065234 suspension | FDA record does not establish local stock |
| Product family guidance | Cephalexin dosage forms | Distinguish unit strength from measured liquid volume |
For capsules, the documented 250 mg Lupin product uses NDC 68180-121 and the 500 mg product uses NDC 68180-122. The label's packaging information includes bottles of 100 and 500, which should not be confused with the patient's prescribed dose count. The two products also have different capsule sizes and green/white coloring with strength-specific imprints.
The suspension label provides separate product records for 125 mg/5 mL and 250 mg/5 mL and multiple prepared-bottle volumes. For example, NDC 68180-440-01 identifies a 100 mL package of the lower concentration and 68180-441-01 a 100 mL package of the higher concentration. The pharmacy must prepare the powder according to its own label and dispense the prescribed measured volume.
The Lupin capsule label revised in August 2026 and the oral-suspension record updated in June 2026 are separate pieces of evidence. A date in the prescribing information helps establish which instructions were in force for the published product record; it does not reveal whether a retailer received a shipment or that a new drug was launched.
When researching product status, distinguish each label's ANDA from NDC package information. A recent revision to dosing, indications or warning language affects interpretation of the label without converting the linked record into a live inventory feed. Regulatory status and a physical fill are questions answered by different sources.
On the capsule side, NDC 68180-121 and 68180-122 differentiate labeled strengths. On the suspension side, 68180-440 and 68180-441 identify the corresponding 125 mg/5 mL and 250 mg/5 mL prepared products in the cited record. Package-level suffixes identify particular bottles; they are not patient-specific dosing instructions.
FDA cautions that an NDC listing does not itself prove an application is approved. Here, the separately identified ANDA information helps interpret the Lupin record, while a pharmacist verifies the actual item to be dispensed. The number is especially useful when a consumer asks about a specific concentration or previous generic manufacturer.
The cited Lupin capsule and oral-suspension prescribing information explicitly says the products were manufactured for Lupin Pharmaceuticals, Inc. and manufactured by Lupin Limited in Mandideep, India. This supports a more precise description than the blanket statement that the firm with the U.S. address must be the factory. Both entities have defined roles in these label documents.
Another company can appear as a repackager or distributor of a Lupin-origin package. That does not automatically mean the manufacturer of the active capsules or powder changed. For a repackaged product, compare its source NDC and labeling chain rather than guessing manufacture from the company that printed the final bottle label.
Lupin's 250 mg label describes a white body and dark green cap, imprinted '250' and 'LUPIN'. The 500 mg label describes a light green body and dark green cap, imprinted '500' and 'LUPIN'. These are useful examples of manufacturer-specific identification, not standard appearances for all cephalexin capsules.
If a previously supplied Lupin capsule is replaced by a Teva or another approved generic, the imprint and shell color may change. The pharmacist should check the product, equivalent form and strength and counsel on the new package. Patients should never identify an unknown pill by a web image alone.
The Lupin suspension record is explicit about both 125 mg per 5 mL and 250 mg per 5 mL concentrations. A 5 mL volume from one bottle does not contain the same cephalexin amount as 5 mL from the other. The pharmacy's final label should specify the prepared concentration, milliliters per prescribed administration and disposal date.
This information differs from capsule identification. A pharmacist normally reconstitutes the powder according to product-specific directions, then supplies a metric dosing device. Storage after mixing and pediatric prescription checks address handling questions that do not arise with a whole capsule.
A switch away from a Lupin-labeled capsule to another manufacturer's eligible generic should be evaluated against the written prescription, route, dosage form, strength and FDA therapeutic-equivalence record as applicable. That is different from replacing a Lupin capsule with suspension, which requires verification of the measured-volume instructions and may need prescriber involvement.
The presence of two dosage-form families within the Lupin records does not make the formulations interchangeable. In particular, caregivers should not keep using a previous bottle's milliliter directions if a pharmacy dispenses a different suspension concentration. See the generic substitution guide for the product-matching framework.
A request for Lupin cephalexin should specify whether the written order is for capsules or suspension. A pharmacist can use the relevant strength or concentration and NDC family to investigate availability; a simple request for 'Lupin cephalexin' does not identify the full item. Current stock and orderability require inquiry with the actual dispensing location.
Prices for a capsule count and prepared suspension volume cannot be compared as if they are equivalent packages. Confirm the entire prescription quantity, pharmacy preparation and any insurer or discount conditions. The liquid cost guide covers the additional parameters relevant to Lupin suspension products.
Both Lupin dosage-form families contain cephalexin and carry antibiotic safety considerations relating to hypersensitivity, diarrhea, renal clearance and appropriate bacterial indications. Choosing a labeled generic company does not remove the need to evaluate whether cephalexin is a suitable drug or create reliable activity against MRSA.
The liquid products have extra practical safety steps: correct preparation, shaking, measurement and post-mixing storage. For the capsule products, identity verification centers on the strength and whole-unit instructions. A pharmacy professional should reconcile the prescribed product when a new label or concentration is supplied.
For a Lupin capsule, verify the exact 250 mg or 500 mg product, its imprint and the corresponding NDC against the dispensed package. For suspension, confirm 125 mg/5 mL versus 250 mg/5 mL, final prepared volume, the current pharmacy directions and the supplied measuring device. The same company name must not conceal a dosage-form mismatch.
If the pharmacy intends to dispense a different manufacturer or product, ask it to explain what remains equivalent and what instructions change. Regulatory identifiers are helpful, but only the dispensing pharmacy can confirm the actual available item. Check the availability guide for next steps and the manufacturer index for other recorded companies.
Separate DailyMed records document Lupin-associated 250 mg and 500 mg capsules and oral suspension at 125 mg/5 mL and 250 mg/5 mL.
The cited capsule record lists 68180-121 for 250 mg and 68180-122 for 500 mg. Ask the pharmacist which specific package NDC is dispensed.
It describes two concentrations, 125 mg/5 mL and 250 mg/5 mL, with product and package identifiers. The pharmacy must confirm preparation and individual dosing directions.
The capsule and suspension labels name Lupin Limited in Mandideep, India as manufacturer and Lupin Pharmaceuticals, Inc. as the company for which they are made. This description applies to those records.
No. The dosage forms require different administration instructions, and an authorized professional must assess any proposed change.
No. NDCs identify registered package presentations but do not establish live inventory at a particular pharmacy.
An appropriately equivalent approved product may be dispensed when permitted by the prescription and applicable law. The pharmacist must check the precise product.
Yes. Both the capsule and oral-suspension products are prescription-only in the United States.